18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

24 August 2020 - Event

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

IMPORTANT UPDATE: Due to the Coronavirus situation, the AMR Conference had to be postponed to 24–25 August in Basel, Switzerland.…

BEAM News
Member News
Events

Latest news of BEAM Alliance

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

06 April 2020 - AGILeBiotics B.V.

AGILeBiotics B.V. appoints new CEO Victor Schut

AGILeBiotics BV was launched in March 2017 by the co-founder Dr. Andreas A. Bastian and is focused on the development…

11 March 2020 - DEINOVE

DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance

The AGIR program aims to explore the antimicrobial potential of rare bacterial strains with the objective of identifying new antibiotic…

25 February 2020 - ALLECRA THERAPEUTICS

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

“The superiority demonstrated in the primary endpoint, at test of cure, combined with a comparable safety profile to that of…

11 February 2020 - Da Volterra

Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients

“Results of this study showed that DAV132 could be safely administered to protect patients’ intestinal microbiota from antibiotic-induced disruption, thus…

05 February 2020 - MaaT Pharma

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

The proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980),of MaaT’s lead compound, MaaT013, in…

27 January 2020 - DEINOVE

DEINOVE: Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections

"The start of this Phase II clinical trial is a significant step forward for DEINOVE and a great hope for…

page 1/17

Events

24 August 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

IMPORTANT UPDATE: Due to the Coronavirus situation, the AMR Conference had to be postponed to 24–25 August in Basel, Switzerland.…

13 July 2020

Curious2020 – Future Insight

In 2020 the Future Insight Prize will be given out in the area of Multi Drug Resistance to enable a…

30 June 2020

REVIVE Webinar: Clinical development of antimicrobials – Phase 1 development challenges

Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)

09 June 2020

REVIVE Webinar: Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

Topics discussed will include: - Understanding the inherent challenges associated with PK/PD of BL/BLI combinations - Demonstrating new approaches to…

12 May 2020

REVIVE Webinar: Probability of target attainment analyses for dose selection in antimicrobial drug development

Topics discussed will include: - An overview of what is meant by the probability of target attainment (PTA) - How…

05 May 2020

Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progress

ONE health approach MULTIPLE answers: Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progress

05 May 2020

REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

In this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…

28 April 2020

REVIVE Webinar: Inhaled antimicrobials: Do we get the drug to the bug?

In this webinar, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this…

28 April 2020

COVID-19 human challenge trials – what will be the regulatory considerations?

The objective of this webinar (45mn presentation / 15mn Q&A) is to explore the potential of CHIM, COVID-19 regulatory considerations,…

page 1/6